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The polymorphism of killer cell immunoglobulin-like receptors (KIR) has been associated
with several diseases, including infection, autoimmunity and cancer. KIR molecules are a
family of receptors expressed on the surface of natural killer cells (NK), frontline defense
of innate immunity against microorganisms and neoplastic cells. Some studies have
shown conflicting results concerning the role that KIR polymorphism plays in tumor
susceptibility, particularly in leukemia and lymphoma. Interestingly, the presence of HLA
ligands is sometimes strongly associated with several types of cancer and apparently is
not related with their interaction with KIR. This manuscript briefly reviews the uncommon
polymorphism of KIR and critically summarizes the recent findings with regards of the
importance of KIR variation for cancer susceptibility.
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INTRODUCTION
Natural killer (NK) cells were initially discovered because of their ability to kill virus-induced
murine leukemic cells without prior sensibilization (Kiessling et al., 1975; Herberman and Ortaldo,
1981) and have been implicated in tumor surveillance and early recognition of microbial infections.
NK cells present a variety of surface receptors that can either enhance or diminish their response
against the target cell. That includes the killer cell immunoglobulin-like receptors (KIR), encoded
by a region at chromosome 19 called leukocyte receptor complex (LRC; Wilson et al., 2000).
The KIR gene complex, located at 19q13.42 (Wende et al., 1999; Liu et al., 2000), consists of a
cluster of homologous genes that has suffered extensive expansion and contraction (Wende et al.,
1999; Martin et al., 2003). Fourteen KIR genes (KIR2DL1-5, KIR2DS1-5, KIR3DL1-3, KIR3DS1,
and two pseudogenes (KIR2DP1 and KIR3DP1) have been described. Not all KIR genes are present
in all individuals; this uncommon presence/absence polymorphism generates a broad variety of
haplotypes that differ among individuals and populations. The diversity of haplotypes combined
with increased number of alleles in each locus make nearly impossible two non-related individuals
to carry the same KIR variants.
The KIR polymorphism has been studied in several populations across the globe (Norman
et al., 2001; Augusto et al., 2012b, 2013, 2015a, 2016; Hollenbach et al., 2012, 2013) and more
than 500 KIR gene-content genotypes have been described among over 200 worldwide populations
(Gonzalez-Galarza et al., 2015). However, allelic diversity is still poorly known.
The nomenclature of KIR genes is based on the structure of the mature protein.
KIR genes encode two or three (2D or 3D) extracellular immunoglobulin domains that
may have short (S) or long (L) cytoplasmic tails (Colonna et al., 1996). Except by
KIR2DL4 (Kikuchi-Maki et al., 2003), all molecules that present long cytoplasmic tails
are inhibitory and all KIR that present short tails transduce activating signals. KIR
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haplotypes can be divided in two major groups: (1) haplogroup
A, which classically consists of a fixed number of genes, mostly
inhibitory; and (2) haplogroup B, composed by a large variation
of gene-content combinations, characterized by the presence of
more activating genes (Uhrberg et al., 2002).
HLA (human leukocyte antigens) class I are MHC (major
histocompatibility complex) molecules that bind self and non-
self peptides and display them on the cell surface for recognition
by appropriate cells of the immune system. Additionally, HLA
are known ligands for KIR. HLA-C2 allotypes are recognized by
KIR2DL1 (Wagtmann et al., 1995; Fan et al., 1996; Winter and
Long, 1997); KIR2DS1 also binds HLA-C2, but at lower affinity
(Stewart et al., 2005). HLA-C1 and some C2 allotypes are bound
by KIR2DL2/3 (Winter et al., 1998), and predicted to be ligand for
KIR2DS2/3. HLA function is primarily related to presentation of
antigens and regulation of immune responses. During the course
of evolution, HLA-A and HLA-B apparently kept their main role
as T cell receptor (TCR) ligands while HLA-C seems to have had
evolved as primarily KIR ligands (Older Aguilar et al., 2010). Still,
several HLA-A and -B molecules interact with KIR. HLA-Bw4,
that comprises about 40% of all HLA-B molecules (Müller et al.,
1989) plus a subset of HLA-A (A∗23, A∗24, and A∗32; Kostyu
et al., 1980), are recognized by KIR3DL1 (Cella et al., 1994; Stern
et al., 2008). Despite the lack of direct evidence (Gillespie et al.,
2007; O’Connor et al., 2007), the homology with KIR3DL1 and
the numerous disease association studies suggest that KIR3DS1
also recognizes HLA-Bw4. KIR3DL2 recognizes HLA-A3/A11
(Döhring et al., 1996; Hansasuta et al., 2004), B27 (Shaw et al.,
2014; Hatano et al., 2015) and HLA-F (Goodridge et al., 2013). As
product of gene conversion with KIR3DL2, KIR2DS4 also binds
HLA-A11 (Graef et al., 2009) andHLA-F (Goodridge et al., 2013).
HLA-A11 is also a ligand for KIR2DS2 (Liu et al., 2014).
KIR polymorphism has been associated with infection,
autoimmunity and cancer (van der Slik et al., 2003; Khakoo
and Carrington, 2006; Yamada et al., 2007; Kulkarni et al.,
2008; Augusto et al., 2012a, 2015b). The importance of KIR for
reproduction is also well-documented (Hiby et al., 2004, 2014;
Trowsdale and Moffett, 2008; Nakimuli et al., 2015). There is
strong evidence thatKIR andHLA are coevolving as an integrated
system (Augusto and Petzl-Erler, 2015) and that KIR-driven
pressures are balancing HLA haplotypes (Capittini et al., 2012;
Fasano et al., 2014; Nemat-Gorgani et al., 2014; Augusto et al.,
2015a).
As consequence of infection or malignancy, abnormal cells
may exhibit reduced expression of self-MHC molecules. NK
cells are able to recognize and to attack those cells with low
expression of self-MHC molecules (Parham, 2004). Over the
last two decades, KIR genes have been reported among those
most strongly associated with disease susceptibility. Because
the recognition of HLA by KIR modulates NK function, and
also because these cells are important for attacking tumors,
variation in KIR and HLA have been thought to intensely
interfere in the risk of developing cancer. This hypothesis was
corroborated by case control studies that showed association
of KIR presence/absence and leukemia (Verheyden et al., 2004;
Zhang et al., 2010). However, as we critically discuss in
this review, as more case-control studies have further been
performed, it now seems that the role of KIR presence/absence
variation in cancer susceptibility may not be as strong as initially
believed.
KIR POLYMORPHISM IN LEUKEMIA
Acute lymphoblastic leukemia (ALL) is a malignancy in the
bone marrow that leads to abnormal production and consequent
excess of juvenile lymphocytes. ALL comprises ∼75% of all
cases of leukemia and normally occurs in children. ALL is
a heterogeneous group of cancers that typically implicates B-
or T-cell precursors, therefore subdivided in B-ALL or T-
ALL. Differently, chronic lymphocytic leukemia (CLL) is a
slow-growing tumor of lymphoid cells and usually occurs in
individuals over 55 years of age. Myeloid leukemia causes rapid
growth of myeloid cells; its acute form (AML) occurs either in
children or in adults and its chronic form (CML) affects primarily
adults.
KIR presence/absence in leukemia was initially explored by
Verheyden et al., who reported KIR2DL2 and KIR2DS2 increased
in patients (Verheyden et al., 2004). Both genes are present in
haplogroup B; therefore, the authors could demonstrate that
haplotype A was protective (Pc = 0.01). Primarily inhibitory
genes compose haplotype A, suggesting that inhibitoryKIR could
protect against leukemia. Limitations of this study were the
mixture of all four types of leukemia listed above within the
patient group and the fact that the impact of KIR polymorphism
in each form is not necessarily the same. Despite these
limitations, the association of KIR polymorphism and leukemia
appeared substantial. However, these results were not totally
supported in a larger Chinese cohort (Zhang et al., 2010).
Zhang and colleagues showed that KIR2DL2was not significantly
increased in patients (p = 0.10). The presence of KIR2DS4,
however, was significantly increased in the total patients’ sample
(OR = 1.76, p = 0.008), but this effect seemed to be driven by
CML subgroup (OR = 3.29, p < 0.001). Although Zhang’s study
did not analyzeKIR haplotypes, activatingKIRwere slightly more
frequent in patients (not significant), what partially corroborated
Verheyden’s findings. In opposition to all these previous results,
however, Middleton et al. showed that KIR2DL2 was protecting
against leukemia (Middleton et al., 2009).
In 2011, Almalte and colleagues analyzed a Canadian-French
cohort composed by 145 B-ALL patients and 30 T-ALL and
compared them to 245 controls (Almalte et al., 2011). In that
study, the authors showed strong protective associations for
the presence of all six activating KIR analyzed. They have not
analyzed presence/absence of inhibitory genes, what challenge
the interpretation those results due to the impossibility of
analyzing the linkage disequilibrium between loci or verifying
the KIR genotypes/haplotypes. Remarkably, an European cohort
was further analyzed by Babor et al. and their results diverged
from all former studies (Babor et al., 2012). Babor et al. reported
no association between KIR presence/absence and leukemia,
despite the fact that KIR frequencies in Babor’s Canadian-French
cohort did not differ from the cohorts from other studies. After
that, another research group analyzed over 300 patients and
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performed another study (Oevermann et al., 2015). Applying
careful and rigorous analyzes, Oevermann et al. corroborated
Babor’s results and reported absence of association of KIR
presence/absence and leukemia. Lack of association was reported
again in Thai patients (Vejbaesya et al., 2014).
Subsequent results brought some light to this discussion
by showing the presence of homozygosity for haplotype A
was associated with increased risk of developing leukemia in
Hispanic, but not in Euro-descendants (de Smith et al., 2014).
de Smith’s explanation was that possibly the role played by KIR in
leukemia may vary among ethnic groups.
Interestingly, three studies have shown stronger associations
of leukemia with HLA: HLA-C2 (Babor et al., 2014) and specially
HLA-Bw4 (Bw4/Bw4; OR = 3.9, p = 0.01; de Smith et al., 2014)
and Bw4Ile80 (OR = 3.32, p = 0.0005). Although Bw4 and C2
are putative KIR ligands, due to conflicting results regarding KIR
in leukemia, it is difficult to believe that these HLA associations
are related to their interaction with KIR, but probably other
HLA-related immune mechanisms.
Together, all these studies lead us to interpret that KIR genes
probably don’t play a major role in leukemia susceptibility, and
this effect may vary in different ethnic groups. Additionally,HLA
polymorphism has a stronger effect in leukemia susceptibility
than KIR. This conclusion is also supported by another study,
which showed only a trend of association for the presence of five
or six activating KIR genes (p = 0.06), but a strong association
for the presence of Bw4 (OR = 0.56; p = 0.005) in CLL patients
(Karabon et al., 2011). Another interesting result from this same
study is that, in general, the combinations KIR3DL1/S1+Bw4
presented similar odds ratios when compared to Bw4 alone. The
association of the pair KIR3DS1+Bw4 (OR = 0.46; p = 0.003)
being similar to Bw4 individually suggests that the effect appears
to be driven mostly by Bw4. To explore KIR-HLA in the allelic
level or expression studies like the one performed by Obama et al.
(2007) could be a key to bring some light to this subject.
LYMPHOMA AND MULTIPLE MYELOMA
The presence of large tumor cells derived from a germinal center
B cell, known as Hodgkin and Reed-Sternberg, characterizes
Hodgkin lymphoma (HL; Re et al., 2005). Epstein-Barr virus
(EBV) is the major environmental factor associated with HL;
approximately 40% of HL patients in the Western community
tested positive for EBV (Küppers, 2009). Considering the
importance ofKIR for virus elimination, it is plausible to consider
them as candidate genes for HL association studies. A familial
study with 90 French families and 255 first-degree siblings was
the first analysis ofKIR polymorphism inHL (Besson et al., 2007).
They reported negative association for the presence of KIR3S1,
KIR2DL5, KIR2DS1 and KIR2DS5 (0.42 < OR < 0.56; 0.006 <
P < 0.05). In that same study, they could not replicate their
own results in a case-control study with 68 patients. Lack of
association was also reported in a Lebanese case control study
with 41 patients and 120 controls (Hoteit et al., 2015). It is
important to notice that both case-control studies that reported
lack of association were composed of small samples, what makes
difficult to exclude the relevance of KIR polymorphism for HL
pathogenesis. Furthermore, a familial study is more powerful
than a case-control study, especially in the example above, in
which Besson et al. performed deep analyzes, including EBV
status of each HL patient.
KIR variation was also studied in non-Hodgkin lymphomas
and multiple myeloma. Similarly from what was shown for
ALL, no associations were seen for individual KIR genes in
diffuse large B-cell lymphoma (DLBCL; Vejbaesya et al., 2014).
Despite the lack of association with KIR variation in DLBCL,
significant association was reported for the presence of HLA-Bw4
(OR = 0.39; p = 0.003). Presence of HLA-Bw4 alone showed
similar odds ratio when comparing to the receptor/ligand pair
KIR3DL1+HLA-Bw4 (OR= 0.34; p= 0.0006), what suggests that
HLA alone was driving the effect. In multiple myeloma, KIR2DS5
and some alleles of KIR2DS4 were associated with increased risk
(Hoteit et al., 2014), but again, the sample size was not large
enough to allow more conclusive assumptions. Comprehensive
studies with large and well-characterized cohorts need to be
performed to verify the real impact of KIR-HLA in these diseases.
BREAST CANCER
A pilot study analyzed the presence/absence of KIR in breast
cancer (Ozturk et al., 2012). In that study, the authors
analyzed 33 patients and 77 controls and reported borderline
associations: KIR2DS1 associated with increased risk (p = 0.03)
and KIR2DL1 increased in controls (p = 0.02). In addition, the
authors performed allelic typing for KIR2DS4 and the alleles
KIR2DS4∗003/4/6/7 were overrepresented in controls (p= 0.03).
Although the authors suggested that KIR variation might be
involved in breast cancer pathogenesis, the small cohort and the
borderline associations didn’t provide conclusive results. These
suggestions could not be corroborated by another study in a
larger cohort of predominantly euro-descendants from Brazil
(230 patients and 278 controls; Jobim et al., 2013). Jobim et al.
reported a strong association for the presence of KIR2DL2 (OR
= 2.7; p < 10−8) and for the presence of HLA-C1 (OR = 2.7;
p < 10−7). The strong associations reported for breast cancer
in the Brazilian cohort suggest that KIR2DL2 combined with its
ligand C1 are, in fact, altering susceptibility to breast cancer. It
is important to notice that the combination KIR2DL2+C1 in the
absence of KIR2DS2 presented odds ratio as strong as 9.9 (Pc <
0.001).
COLON AND RECTAL CANCERS
Absence of association ofKIRwith colorectal cancer was reported
in Europeans (Middleton et al., 2007); different from Koreans,
in which KIR2DS5 was increased in patients (OR = 1.9; p =
0.0007; Kim et al., 2014). Al Omar et al. also reported lack of
association of KIR and colon cancer (Al Omar et al., 2010);
interestingly, they showed a strong association of the presence
of HLA-Bw4 (Bw4Ile80, OR= 3.1, p= 0.0001; Bw4The80, OR=
0.3, p= 0.0001 in individuals KIR3DL1+Bw4+). HLA-Bw4Ile80
is a stronger ligand for KIR (Cella et al., 1994); although this
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association suggests that KIR may interfere in the colon cancer
susceptibility, it is important to note the lack of association for
KIR+HLA pairs.
OTHER CANCERS
Figure 1 and Table 1 summarize the associations and effect seen
for KIR and ligands in several types of cancer. Nasopharyngeal
cancer (NPC) is another example of neoplasm in which HLA
polymorphism plays a major role in its susceptibility. In Chinese,
HLA-B58 and HLA-A11 have been shown to confer risk and
protection, respectively, for the development of NPC (Chan et al.,
1983; Hildesheim et al., 2002; Lu et al., 2003). Even though
HLA-A11 is a ligand for KIR3DL2 and KIR2DS4 (Döhring
et al., 1996; Hansasuta et al., 2004; Graef et al., 2009), these
relationships have not been investigated in NPC yet. The
presence of five or more activating KIR conferred risk to EBV
positive NPC patients; HLA-Cw4 was also reduced in NPC
patients (Butsch Kovacic et al., 2005).HLA polymorphism seems
to play a strong effect also in other cancers, such melanoma and
ovarian, when comparing to a small or no effect of KIR for the
susceptibility of those diseases (Naumova et al., 2005; Giebel et al.,
2014).
The combination KIR2DL2+C1/C1 was strongly associated
with protection in kidney patients (OR = 0.08; p = 0.002, n =
40 patients). Similarly from what was seen for breast cancer, the
combination KIR-HLA showed stronger effect than either KIR or
HLA isolated, suggesting the role of KIR-HLA combinations for
the risk to develop this disease (Naumova et al., 2007; Al Omar
et al., 2010; Giebel et al., 2014).
FIGURE 1 | Summary of the cancers for which KIR polymorphism have been analyzed. Blue boxes = statistically significant association of cancer with KIR
and/or HLA ligand; yellow boxes = borderline associations, lack of association or studies with reduced sample size.
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TABLE 1 | List of the main association studies that analyzed KIR polymorphism in cancer.
Ethnicity OR/effect P N References
Leukemia 2DL2 Euro Risk 0.007 94 Verheyden et al., 2004
2DS2 Risk 0.022 94
A/A genotype Protection 0.011 94
2DS4 Asian 1.76 0.008 263 Zhang et al., 2010
2DS4 in CML 3.29 < 0.001 135
2DL2 Euro 0.61 0.029 158 Middleton et al., 2009
2DL2 in CML 0.39 0.004 52
Bw4 Ile80 1.72 0.018 158
Bw4 Ile80 in AML 3.32 < 0.001 54
2DL2+C1 0.55 0.009 158
2DL2+C1 in CML 0.28 < 0.001 52
2DS2+C1 0.58 0.018 158
2DS2+C1 in CML 0.33 0.002 52
2DS1 Euro 0.55 0.020 100 Almalte et al., 2011
2DS2 0.19 < 0.001 100
2DS3 0.32 < 0.001 100
2DS4 0.49 0.004 100
2DS5 0.32 < 0.001 100
3DS1 0.27 < 0.001 100
>4 Activating KIR 0.06 < 0.001 100
Lack of association with KIR Euro NA 220 Babor et al., 2012
A/A Hispanic 1.86 0.03 114 de Smith et al., 2014
A/A Euro NA 0.37 76
Bw4/Bw4 Euro 3.93 0.01 76
Lack of association for KIR2DL1/S1 alleles Euro NA 320 Babor et al., 2014
C1/C1 in ALL 0.69 0.005 320
Lack of association with KIR in B-CLL Euro NA 197 Karabon et al., 2011
Bw4 0.56 0.005 197
Lymphoma 3DS1 (familial study) in HL Euro 0.44 0.006 345* Besson et al., 2007
2DL5 (familial study) in HL 0.56 0.02 345*
2DS1 (familial study) in HL 0.42 0.01 345*
2DS4full (familial study) HL 2.22 0.03 345*
Lack of association with KIR (case-control) NA 68
Lack of association with KIR in HL Arab NA 41 Hoteit et al., 2015
Lack of association with KIR in FL Arab NA 20 Khalaf et al., 2013
Lack of association with KIR in DLBCL Asian NA 60 Vejbaesya et al., 2014
Bw4 in DLBCL 0.39 0.003 60
3DL1+Bw4 in DLBCL 0.34 0.001 60
Multiple myeloma 2DS4*001/002 Arab Risk 0.04 34 Hoteit et al., 2014
2DS5 Risk 0.007 34
Nasopharyngeal >5 Activating KIR Asian 3.40 0.07 378 Butsch Kovacic et al., 2005
Breast cancer 2DL1 Euro Risk 0.03 34 Ozturk et al., 2012
2DS1 Risk 0.03 34
(Continued)
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TABLE 1 | Continued
Ethnicity OR/effect P N References
2DS4*003/4/6/7 Protection 0.03 34
2DL2 Euro 2.18 < 0.001 230 Jobim et al., 2013
C1 2.71 < 0.001 230
2DL2+C1 in absence of 2DS2 9.95 < 0.001 230
Colorectal cancer Lack of associations Euro NA 128 Al Omar et al., 2010
2DS5 Asian 1.9 0.007 241 Kim et al., 2014
Lack of association with KIR Euro NA 75 Al Omar et al., 2010
Bw4 Ile80 in 3DL1+Bw4+ individuals 3.10 < 0.001 75
Bw4 Thr80 in 3DL1+Bw4+ individuals 0.30 < 0.001 75
Lack of associations Euro NA 90 Middleton et al., 2007
Melanoma Lack of association with KIR Euro NA 50 Naumova et al., 2005
C2 0.27 0.017 50
Ovarian cancer Lack of association with KIR Euro NA 142 Giebel et al., 2014
C1 3.07 0.002 103
Kidney cancer 2DL3+C1 Euro 5.90 0.009 40 Al Omar et al., 2010
2DL2+C1- 0.08 0.002 40
Kaposi’s sarcoma 2DS1 Euro 3.82 0.008 32 Guerini et al., 2012
3DS1 4.00 0.006 32
2DS1+C2 4.24 0.01 32
KIR3DS1+Bw4 Ile80 Euro 0.60 0.01 250 Goedert et al., 2016
Lung cancer 2DL3+C1/C1 Euro 0.58 0.007 186 Al Omar et al., 2010
Prostate cancer Lack of associations Euro NA 185 Portela et al., 2012
Bladder cancer 3DL1 Euro Risk 0.011 Middleton et al., 2007
2DS4 Risk 0.011
Laryngeal cancer Lack of associations Euro NA 70 Middleton et al., 2007
Thyroid cancer 2DS5 Arab 1.77 0.036 85 Ashouri et al., 2012
Neuroblastoma 2DL2 Euro 1.57 0.019 201 Keating et al., 2015
2DS2 1.66 0.008 201
Except for Besson et al. (2007), all cited manuscripts performed case-control studies. “Euro” includes European and Euro-descendant populations. OR = odds ratio; P = p-value;
N = patient sample size; A/A = homozygote genotype for haplogroup A; CML = chronic myeloid leukemia; AML = acute myeloid leukemia; HL = Hodgkin’s lymphoma; FL = follicular
lymphoma; DLBCL= diffuse large B-cell lymphoma. Red= risk (OR> 1); blue= protection (OR< 1); green= not associated (NA); *this is a familial study composed with 345 individuals
in total. Not all families were informative for all analyzes.
Activating KIR genes were associated with Kaposi’s sarcoma
(KS), a complication of KS-associated herpesvirus (KSHV)
infection (Antman and Chang, 2000). Activating genes
(KIR2DS1, KIR3DS1, and the combination KIR2DS1+HLA-C2)
were significantly increased in individuals with classic KS
(Guerini et al., 2012). Goedert et al. showed that KIR activation
might decrease the risk of KSHV infection in an Italian cohort,
while might enhance KSHV dissemination and progression to
KS if infection occurs (Goedert et al., 2016).
CONCLUDING REMARKS
Despite the number of studies, it is still difficult to fully
comprehend the role of KIR variation in cancer. One of the
reasons is the reduced number of studies that analyzed large
and well-characterized cohorts. Some studies have shown strong
association with some types of cancer, but lack of association in
several other studies and conflicting results suggest that the role
of KIR presence/absence polymorphism may vary in different
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cancers. It is also clear that further studies with larger cohorts are
needed.
Leukemia and lymphoma are examples of diseases for
which mostly divergent results have been reported. It is
interesting, however, that despite the conflict regarding KIR,
the presence of HLA ligands has been consistently associated
with different types of cancer. Even more interesting is the
fact that many studies have shown that combinations KIR-HLA
did not exhibit stronger effect than HLA alone. This suggests
that the associations with HLA are possibly not related to
KIR interaction. All these studies together suggest that KIR
presence/absence polymorphism possibly does not play a major
role in cancer. Considering the importance of NK for killing
neoplastic cells, and the growing number of studies reporting
KIR-HLA association with diseases, this conclusion can be quite
intriguing.
It is important, however, to emphasize that lack of association
with KIR presence/absence does not mean that KIR is not
relevant for cancer. First, presence/absence polymorphism
doesn’t take the allelic polymorphism in consideration. KIR
allelic variation is poorly known and rarely studied in diseases.
Lack of genetic association does not discard the possibility of
the cancer being associated with KIR differential expression
levels, what confers another layer of complexity. Finally, the
epigenetic mechanisms that regulate KIR-HLA should be studied
especially in cancer, as it has been extensively demonstrated the
importance of epigenetic regulation for tumor development. The
comprehension of how KIR-HLA may be implicated in cancer
is beyond presence/absence polymorphism, and perhaps beyond
genetics. Different approaches have to be carefully considered,
not only for KIR-HLA, but also for all genes that could impact
cancer susceptibility.
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